Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biota Scientific Management, a wholly subsidiary of Biota Holding, has received a grant of $231m from the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS) for the advanced development of Laninamivir.
Subscribe to our email newsletter
Laninamivir is an influenza antiviral, known as a neuraminidase inhibitor (LANI) and a treatment for influenza.
The contract is designed to provide US based manufacturing and clinical data to support a new drug application (NDA) for Laninamivir, to the US Food and Drug Administration.
Biota CEO Peter Cook said the BARDA contract will be a major contributor to a timely introduction of the product and will create the opportunity to significantly develop Biota’s business in the US.